Kura Oncology, Inc. (KURA)
Nasdaq: KURA · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2008
Income statement, as filed
In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in thousands. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
| Report filed | Mar 5, 2026 | Feb 28, 2025 | Feb 27, 2024 | Feb 23, 2023 | Feb 24, 2022 | Feb 24, 2021 | Feb 25, 2020 | Mar 5, 2019 | Mar 12, 2018 | Mar 14, 2017 |
| Revenue | 67,482 | 53,883 | 0 | · | · | · | · | · | · | · |
| Research and development | 251,074 | 169,967 | 115,235 | 92,812 | 84,721 | 60,397 | 47,826 | 46,787 | 26,426 | · |
| Selling, general and administrative | 119,982 | 77,111 | 50,569 | · | · | · | · | · | · | · |
| General and administrative | · | 77,111 | 50,569 | 47,053 | 46,537 | 31,502 | 19,653 | 16,096 | 9,651 | · |
| Total operating expenses | 371,113 | 247,078 | 165,804 | 139,865 | 131,258 | 91,899 | 67,479 | 62,883 | 36,077 | 28,367 |
| Operating income | -303,631 | -193,195 | -165,804 | -139,865 | · | · | · | · | · | · |
| Interest expense | 1,512 | 1,619 | 1,549 | 229 | 414 | 578 | 580 | 970 | 888 | 577 |
| Interest and investment income | · | · | · | · | · | · | · | · | 751 | 499 |
| Total non-operating income (expense) | 25,262 | 21,230 | 13,173 | 4,025 | 792 | 2,274 | 4,339 | 2,436 | 643 | 807 |
| Income before income taxes | -278,369 | -171,965 | -152,631 | -135,840 | · | · | · | · | · | · |
| Income tax expense | 297 | 2,018 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | -278,666 | -173,983 | -152,631 | -135,840 | -130,466 | -89,625 | -63,140 | -60,447 | -35,434 | -27,560 |
| Earnings per share, basic | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | · | · | · | · |
| Earnings per share, diluted | -3.18 | -2.02 | -2.08 | -2.03 | -1.97 | -1.69 | · | · | · | · |
| Earnings per share, basic and diluted | · | · | · | · | -1.97 | -1.69 | -1.51 | -1.72 | -1.52 | -1.47 |
| Weighted average shares, basic | 87,676 | 86,161 | 73,229 | 66,990 | 66,352 | 53,077 | · | · | · | · |
| Weighted average shares, diluted | 87,676 | 86,161 | 73,229 | 66,990 | 66,352 | 53,077 | · | · | · | · |
| Weighted average shares, basic and diluted | · | · | · | · | 66,352 | 53,077 | 41,946 | 35,191 | 23,237 | 18,701 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseGeneral and administrative the cost of running the company itself
us-gaap:GeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpenseInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestTotal non-operating income (expense) everything outside the business, together
us-gaap:NonoperatingIncomeExpenseIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedEarnings per share, basic and diluted net income per share, where both counts are the same
us-gaap:EarningsPerShareBasicAndDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstandingWeighted average shares, basic and diluted the average count, where both counts are the same
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted